EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2


ABSTRACT

The provisional EULAR recommendations address several aspects of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus, and the disease caused by SARS-CoV-2, COVID-19 and are meant for patients with rheumatic and musculoskeletal diseases (RMD) and their caregivers. A task force of 20 members was convened by EULAR that met several times by videoconferencing in April 2020. The task force finally agreed on five overarching principles and 13 recommendations covering four generic themes: (1) General measures and prevention of SARS-CoV-2 infection. (2) The management of RMD when local measures of social distancing are in effect. (3) The management of COVID-19 in the context of RMD. (4) The prevention of infections other than SARS-CoV-2. EULAR considers this set of recommendations as a ‘living document’ and a starting point, which will be updated as soon as promising new developments with potential impact on the care of patients with RMD become available.

INTRODUCTION

The provisional recommendations address several aspects of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus, and the disease caused by SARS-CoV-2, COVID-19. They address the implications for patients with rheumatic and musculoskeletal diseases (RMD). They have been commissioned by EULAR, and developed under its auspices, in order to guide both rheumatologists and health professionals in rheumatology (HPR) who care for patients with RMD, COVID-19-treated physicians as well as patients with RMD themselves and their family members.

Many (inter)national professional organisations in rheumatology and beyond, as well as government bodies, have issued guidance documents pertaining to the prevention, diagnosis and treatment of SARS-CoV-2 infection and COVID-19. Since generic recommendations do not focus on patients with RMD and their circumstances, EULAR considered it essential to provide a set of recommendations that are applicable to all rheumatologists and HPRs and their patients with RMD in EULAR countries. Guidelines issued by national (professional) organisations can occasionally be more or less restrictive than EULAR recommendations. By no means EULAR intends to outrule existing guidelines at the country level of EULAR member states. EULAR only aims to provide a synthesis of the best available aggregated expert opinion to inform rheumatologists and HPR and patients with RMD about management decisions to be taken in the context of the SARS-CoV-19 epidemic.

SARS-CoV-2 is a new virus and COVID-19 a new disease. Scientific knowledge is rapidly accruing, but methodologically robust information from well-controlled trials and experiments is lacking to date. In contrast, we face a flood of unreliable largely uncontrolled studies and even fake news. It is to be expected that scientific knowledge of the calibre that EULAR usually requires to design and update their recommendations will be lacking for a while. Nevertheless, people with RMD appropriately confront their rheumatologists and HPR with questions about treatment implications and COVID-19-associated anxiety. In turn, rheumatologists and HPR may feel uncertain about how to advise in the best interest of their patients. Therefore, EULAR decided not to wait until robust scientific knowledge becomes available, but to deviate from their standard operating procedures and to convene a task force of international experts to provide provisional guidance for rheumatologists, HPR and patients with RMD. Although the task force was hampered by restrictions of social distancing, preventing them to meet in person—it performed the complete process successfully by videoconferences.

EULAR is committed, in contrast to our usual procedures, to consider this set of recommendations as a ‘living document’ and a starting point, which will be updated as soon as promising new developments with potential impact on the care of patients with RMD become available. These developments will be monitored closely, their quality judged by a team of EULAR methodologists and, after further discussion in the task force, included in an updated version of the recommendations when appropriate.

PROCEDURES

Focus of recommendations

These recommendations pertain to the management of patients with RMD insofar as the current SARS-CoV-2 epidemic and its consequent COVID-19 disease may interfere with usual
management of patients with RMD. These recommendations are
decidedly not focused on the diagnosis or treatment of COVID-
19. There is some focus on so-called ‘inflammatory’ RMD,
because of specific issues that patients with systemic autoim-
mune diseases, partly due to their treatments, may face or may
have concerns about, without excluding all patients with other
types of RMD.

The task force composition
This EULAR task force consists of 22 experts from seven EULAR
member states. Most experts are internationally recognised
rheumatologists and immunologists with many years of clinical
and scientific experience, who fulfil or have fulfilled official
positions in the EULAR organisation. EULAR’s current, past and
incoming presidents (HWJB, GRB, IM, AL JSS), as well as the
current, past or incoming chairs of EULAR’s standing commit-
tees on epidemiology and health services research (PMM, LC,
LG), clinical affairs (UM-L, RBL) and investigative rheumatology
(XM) are members of the task force, among others. The task
force was supported by an expert on viral lung diseases (PO),
an infectious disease specialist (MG), the EULAR vice-
president representing HPR (TAS), the EULAR vice-president representing
patients with arthritis and rheumatism (DW) and a clinical
fellow (FK). The task force was presided by the past-president of
EULAR (HWJB) and selected an overarching steering committee
consisting of three clinically active rheumatologists (RBL, PMM,
HS-K) and one fellow (FK). All task force members had ample
experience with the development of EULAR recommendations
according to EULAR’s standard operating procedures (SOPs).1

Handling potential conflict of interest
In accordance with EULAR’s SOP, task force members are asked
on an annual basis to provide and update their interactions with
third parties (guideline committees, reimbursement bodies, phar-
maceutical industries or other industries) that are not directly
related to all day patient care but may give an impression to
others of conflict of interest (potential COI). The EULAR office
keeps record of these declared potential COIs.

The steering committee’s workflow
First, the steering committee collected, largely from official
websites, existing guidance documents stemming from several
European and non-European countries. Some of these focused
on RMD and were prepared by national professional organisa-
tions of rheumatology (German,2 French,14 Spanish3) or general
medical organisations (UK National Health Service,6 National
Institute for Health and Care Excellence). Others were generic
guidelines, not focusing on RMD (WHO).1 During the process
a set of recommendations by the American College of Rheuma-
tology became available.9

Thereafter, the steering committee proposed five overarching
principles (OPs). In EULAR’s recommendation documents, OPs
usually serve to underpin the content of the subsequent rec-
ommendations; OPs set the stage on which the body of guidance
that follows is built.

Next, the steering committee distinguished four areas of
interest for which recommendations seemed appropriate: (1)
General measures and prevention of SARS-CoV-2 infection.
(2) The management of RMD when local measures of social
distancing are in effect. (3) The management of COVID-19 in
the context of RMD. (4) The prevention of other infections than
SARS-CoV-2.

In total, the steering committee conceived 114 recommenda-
tions (between 2 and 5 per area of interest) that were largely
based on existing guidelines and recent personal clinical experi-
ence of steering committee members. Explanatory information
accompanied each of the proposed OP and recommendations.
The steering committee met three times within a period of 10
days by videoconferencing.

The task force’s workflow
The task force members took notice of the draft recommenda-
tions by email and were given the opportunity to propose
changes, new themes and recommendations. These sugges-
tions were collected by the steering committee and discussed
in a task force meeting by videoconference (14 April). The
steering committee drafted a second proposal, including the
proposed changes, and one new recommendation, which was
discussed 1 week later in a second task force meeting (21 April).
Consensus was reached on 21 April, and the steering committee
was assigned the task to prepare the manuscript. All task force
members commented on and agreed to the final version of the
manuscript before submission.

Target audience
In line with EULAR’s SOP, the task force agreed to target their
guidance primarily on rheumatologists, HPR and patients with
RMD and their families. Secondarily, these recommendations
target public health officials and public health experts by making
them aware of particular problems pertaining to patients with
RMD and their treatments, as well as policy makers, who decide
about measures of social distancing, access to healthcare for
patients with RMD and availability of drugs for patients with
RMD.

Systematic literature research
It was decided upfront that a systematic literature research to
inform the process would not be performed. This is justified on
the current absence of sufficient appropriately controlled clinical
studies or relevant epidemiological reports as to inform a mean-
ingful process.

Formal decision making
A formal voting procedure was not performed. Each expert’s
level of agreement (from 0 (no agreement at all) to 10 (fully
agree)) with the statement was solicited by email for each OP
and recommendation on 23 April. The mean level of agreement,
as well as the proportion of experts with a level of agreement of
at least 8, was calculated.

RESULTS
The task force finally agreed on 5 OPs and 13 recommendations.
The bullet text of these OPs and recommendations can be read in
table 1. Below, an item-by-item discussion is outlined, that
clarifies the choice of themes and wording and sheds more light
on the discussions that have taken place in the task force.

OP 1. To date, there is no evidence that patients with RMD face
more risk of contracting SARS-CoV-2 than individuals without
RMD, nor that they have a worse prognosis when they contract it.
This OP states that, according to current knowledge, patients
with RMD should not be managed differently than individuals
without RMD. It is currently unknown whether a specific RMD
or treatment with a specific drug influences the risk (increase,
decrease or no change in the risk) of developing COVID-19.
While many advisories, including official government bodies
in some countries,\textsuperscript{6} 10–12 postulate an increased risk for patients with inflammatory/autoimmune diseases or those using immunosuppressive drugs, since they extrapolate existing data stemming from registries that such patients have increased risk of some infections.\textsuperscript{13–15} it should be stated clearly that such an association for SARS-CoV-2 and COVID-19 has not (yet) been established. From this OP follows that there is no current basis for preventive measures that are more or less restrictive than those issued for the general population (see recommendations 1 and 2). However, there is also no evidence that patients with RMD, irrespective of their treatment, have a better prognosis than other individuals.

Level of agreement: 9.1±1.2; 84% scored 8/10 or higher.

OP 2. The diagnosis and treatment of COVID-19 in patients with RMD is the primary responsibility of an expert in treating COVID-19, such as a pulmonologist, an internist or a specialist in infectious diseases, dependent on local circumstances.

Table 1  EULAR provisional recommendations for the management of rheumatic musculoskeletal diseases in the context of SARS-CoV-2—April 2020 version

<table>
<thead>
<tr>
<th>Overarching principles</th>
<th>LoA</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean±SD</td>
</tr>
<tr>
<td>1. To date, there is no evidence that patients with RMD face more risk of contracting SARS-CoV-2 than individuals without RMD, nor that they have a worse prognosis when they contract it.</td>
<td>9.1±1.2</td>
</tr>
<tr>
<td>2. The diagnosis and treatment of COVID-19 in patients with RMD is the primary responsibility of an expert in treating COVID-19, such as a pulmonologist, an internist or a specialist in infectious diseases, dependent on local circumstances.</td>
<td>9.3±1.3</td>
</tr>
<tr>
<td>3. Rheumatologists are the leading experts for the immunosuppressive treatments of their patients and should be involved in the decision to maintain or discontinue them.</td>
<td>9.2±2.4</td>
</tr>
<tr>
<td>4. The knowledge about immunosuppressive treatments, including sDMARDs and bDMARDs, for the treatment of severe COVID-19 is rapidly evolving. In view of their expertise, rheumatologists should make themselves available for local-hospital, regional or national guideline committees for COVID-19. The use of immunosuppressive drugs for the treatment of COVID-19 should be a multidisciplinary decision.</td>
<td>9.3±1.4</td>
</tr>
<tr>
<td>5. Availability and distribution of, and access to, sDMARDs and bDMARDs for the treatment of patients with RMD as well as for patients with COVID-19 (but without RMD) is a delicate societal responsibility. Therefore, the off-label use of DMARDs in COVID-19 outside the context of clinical trials should be discouraged.</td>
<td>8.9±1.2</td>
</tr>
</tbody>
</table>

Recommendations

1. Patients with RMD should be strongly advised to comply with all preventive and control measures prescribed by the health authorities in their countries. 9.9±0.5 95

2. Patients with RMD should in general be advised to comply with the same preventive and control measures as patients without RMD. 9.3±1.0 89

3. Patients with RMD who do not have suspected or confirmed COVID-19 should be advised to continue their treatment unchanged, namely NSAIDs; glucocorticoids, sDMARDs, bDMARDs, osteoporosis medications and analgesics, among others. 9.6±0.6 94

4. If the RMD and its drug treatment are stable, and signs or symptoms of drug toxicity are absent, regular blood monitoring and face-to-face rheumatology consultations can be postponed temporarily. If necessary, consultation can take place remotely. 9.6±0.9 94

5. If the RMD is active, if drug therapy has recently been started or needs adjustment, or if signs or symptoms of drug toxicity emerge, patient and rheumatologist should liaise, weigh the risks of a visit to the clinic against the limitations of remote advice and decide together. 9.7±1.0 89

6. If a patient with RMD is offered an outpatient, day care or other type of hospital appointment, patients and members of the rheumatology team should follow local guidance for infection prevention and control, including the use of personal protection equipment if indicated. 9.9±0.2 94

7. Patients with RMD without COVID-19 symptoms who have been in contact with a SARS-CoV-2-positive person should be tested for SARS-CoV-2 themselves. 8.0±2.5 63

8. If a patient with RMD and symptoms of COVID-19 is chronically treated with glucocorticoids, this treatment should be continued. 8.8±1.6 79

9. If patients with RMD experience mild* symptoms of COVID-19, potential treatment changes in DMARDs should be discussed on a case-by-case basis. 8.9±1.4 84

10. Patients with RMD and initially mild symptoms who experience worsening† of COVID-19 symptoms should immediately seek further healthcare advice of an expert in treating COVID-19, such as a pulmonologist, an internist or a specialist in infectious diseases, dependent on local circumstances. 9.8±0.5 94

11. Patients with RMD who are admitted to the hospital because of significant COVID-19 should follow local treatment recommendations for COVID-19 as applied by the treating expert. 9.7±0.8 89

12. Patients with RMD without symptoms of COVID-19 should be advised to update their vaccination status in accordance with the EULAR recommendations for the vaccination of patients with RMD, with a particular focus on pneumococci and influenza. 9.4±1.0 89

13. In patients with RMD treated with cyclophosphamide or glucocorticoids, Pneumocystis jiroveci pneumonia prophylaxis should be considered. 9.3±0.9 89

*See definition of mild symptoms in box 2.
†See definition of worsening in box 2.
‡See definition of significant COVID-19 in box 2.

sDMARD, synthetic disease modifying antirheumatic drug; bDMARD, biologic disease modifying antirheumatic drug; EULAR, European League Against Rheumatism; LoA, level of agreement; NSAID, non-steroidal anti-inflammatory drug; RMD, rheumatic and musculoskeletal diseases; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; sDMARD, synthetic disease modifying antirheumatic drug.
This OP serves to make clear that the diagnosis and treatment of SARS-CoV-2-infection and COVID-19 does not and should not belong to the expertise and responsibility of the rheumatologist or the HPR working in the field of rheumatology. Depending on local (national) circumstances, several different medical specialists take care of these patients.

Level of agreement: 9.3±1.3; 84% scored 8/10 or higher.

OP 3. Rheumatologists are the leading experts for the immunosuppressive treatments of their patients and should be involved in the decision to maintain or discontinue them.

This OP states that the rheumatologist is an important discussion partner in making decisions on drug treatment in patients with RMD, in particular patients that use synthetic or biologic disease modifying antirheumatic drugs (sDMARDs and bDMARDs, respectively) or other drugs that have an immunosuppressive connotation. This OP is important since recent information suggests that clinicians taking care of patients with COVID-19 are tempted to stop all treatments that are believed to be associated with impaired virus clearance, without considering the risk of a flare of the underlying RMD, leading to unwarranted situations and anxiety in patients. The treating rheumatologist is the pre-eminent discussion partner for experts in treating COVID-19 to decide if a drug for RMD can be paused safely or should be continued (see below). The rheumatologist’s role should not be marginalised.

In the task force there was dissent about using the term ‘immunosuppressive’ versus the term ‘immunomodulatory’. The task force finally decided to keep the term ‘immunosuppressive’, since it is the fear for and perception of inappropriate suppression of the immune system that leads to the discontinuation of these drugs in case of COVID-19. Still, some of them do not formally supress the immune system (eg, hydroxychloroquine and sulfasalazine) and bDMARDs that target cytokines formally suppress the immune system (eg, hydroxychloroquine and tocilizumab) has been approved by Food and Drug Administration (FDA) and European Medicines Agency (EMA) for patients with chimeric antigen receptor (CAR) T cell treatment associated CRS and recently by Chinese authorities for severe COVID-19.16

Rheumatologists may possess relevant knowledge about the indications, contraindications and toxicity of DMARDs and cytokine inhibitors and could be consulted by physicians treating patients with COVID-19 and by guideline committees. The term ‘multidisciplinary’ here refers to different medical specialists, but it is obvious that the decision to start, stop or continue treatment with DMARDs or cytokine inhibitors in the end should be a shared decision between patients and physician(s).

Level of agreement: 9.3±1.4; 84% scored 8/10 or higher.

OP 5. Availability and distribution of, and access to, sDMARDs and bDMARDs for the treatment of patients with RMD as well as for patients with COVID-19 (but without RMD) is a delicate societal responsibility. Therefore, the off-label use of DMARDs in COVID-19 outside the context of clinical trials should be discouraged.

This principle elaborates on the potential lack of drug availability for patients with RMD (with or without COVID-19) due to unproven overuse for patients with COVID-19. The best example is the shortage of HCQ for patients with systemic lupus erythematosus, that arose in some countries after rumours that this drug would be effective in COVID-19.17 Similar concerns exist for particular bDMARDs (eg, tocilizumab). ‘Delicate responsibility’ refers to the following dilemma: in the absence of a proven treatment for COVID-19, clinicians will understandably try every drug with possible efficacy in critically ill patients, and publish their successes in case reports. However, by doing so they may unintentionally contribute to creating false hope and conveying wrong information. Since some DMARDs are potentially efficacious in COVID-19, patients with RMD can be affected disproportionally. It is because of this dilemma that off-label medication use outside the context of clinical trials should

Box 1 Cytokine release syndrome

► Cytokine release syndrome (CRS) (also described as cytokine storm, macrophage activation syndrome or secondary haemophagocytic lymphohistiocytosis) is an emergency condition of systemic hyperinflammation that may occur in patients with COVID-19 pneumonia.25 CRS should be suspected in patients with confirmed COVID-19 pneumonia (either by PCR testing or by CT scan) who rapidly deteriorate and experience respiratory failure. Potential biomarkers of CRS are very high levels of C reactive protein, D-dimer, ferritin and IL-6 or a high H Score, which computes a value based on the following components: temperature, organomegaly, number of cytopenias, triglycerides, fibrinogen, ferritin, aspartate aminotransferase, haemophagocytosis on bone marrow aspirate and known immunosuppression.26

DMARDs (such as (hydroxy)chloroquine) are now, rightly or wrongly, propagated for the prevention or treatment of COVID-19. Several bDMARDs (such as interleukin (IL) 6 and IL-1 inhibitors) and janus kinase inhibitors (JAKi) are under investigation for treating severe COVID-19 and are sporadically used ‘off-label’, in particular in patients with COVID-19 with concomitant cytokine release syndrome (CRS; see box 12 for an explanation). The IL-6 receptor blocker tocilizumab has been approved by Food and Drug Administration (FDA) and European Medicines Agency (EMA) for patients with chimeric antigen receptor (CAR) T cell treatment associated CRS and recently by Chinese authorities for severe COVID-19.16

Box 2 Symptoms of COVID-19

**Mild symptoms of COVID-19:**
► These include symptoms of common cold, such as sore throat, running nose, nasal congestion, anosmia or dysgeusia, fatigue, generalised or local myalgia, articulargia without clinical swelling, anorexia, diarrhoea, as well as temperature elevation (>38°C).

**Worsening of mild COVID-19 symptoms:**
► This applies when a patient with formerly mild symptoms of COVID-19 gets fever ≥38°C or subjective shortness of breath or tachypnoea (>20/min) or hypoxia or cyanosis.

**Significant symptoms of COVID-19:**
► These include all of the above, but accompanied by fever (≥38°C) or subjective shortness of breath or tachypnoea (>20/min) or hypoxia or cyanosis.
be discouraged. Physicians that nevertheless decide to treat patients with COVID-19 with DMARDs off-label have a responsibility to document their argumentation and the follow-up of these patients carefully.

Level of agreement: 8.9±1.2; 89% scored 8/10 or higher.

General measures and prevention of SARS-CoV-2 infection

Recommendations 1–3 pertain to general public health measures and precautions. The scope is that of patients with RMD who have no signs of COVID-19 and have not been in contact with patients with COVID-19.

RC 1. Patients with RMD should be strongly advised to comply with all preventive and control measures prescribed by the health authorities in their countries.

In line with OP 1 to date there is no reason to assume that patients with RMD have a higher risk of being infected with SARS-CoV-2, or fare worse if they get COVID-19. Obviously, this means that currently known risk factors for severe COVID-19, including older age, male gender, comorbid cardiovascular disease and obesity, also pertain to patients with RMD.14 This recommendation tells patients and their rheumatologist/HPR to behave like all other individuals in society in their attempts to avoid or control infection. We note that some RMDs share increased prevalence of some of these comorbidities especially metabolic syndrome, cardiovascular disease and obesity.

Level of agreement: 9.9±0.5; 95% scored 8/10 or higher.

RC 2. Patients with RMD should in general be advised to comply with the same preventive and control measures as patients without RMD.

This recommendation reiterations that there is also no reason for patients with RMD to take different measures, given there is no added risk for them. There is also no reason to believe that patients with RMD have more or less risk than others because of their DMARD use.

Level of agreement: 9.3±1.0; 95% scored 8/10 or higher.

RC 3. Patients with RMD who do not have suspected or confirmed COVID-19 should be advised to continue their treatment unchanged, namely NSAIDs, glucocorticoids (GCs), dMARDs, bDMARDs, osteoporosis medications and analgesics, among others.

Based on the same rationale as OP 1, it is unadvisable to change chronic treatment for RMD in patients who are not suspected of COVID-19. This recommendation refers to patients with ‘inflammatory’ RMD, and to all patients with RMD, and serves to reassure those who are concerned about the safety of their drugs with respect to COVID-19.

Level of agreement: 9.6±0.6; 94% scored 8/10 or higher.

Management of COVID-19 in the context of RMD

Recommendations 7–10 refer to scenarios in which a patient with RMD has been in contact with a virus-positive patient or is virus-positive himself/herself. A focus is on the use of (potentially) immunosuppressive drugs, commonly used in patients with ‘inflammatory’ RMD.

RC 4. If a patient with RMD is offered an outpatient, day care or other type of hospital appointment, patients and members of the rheumatology team should follow local guidance for infection prevention and control, including the use of personal protection equipment if indicated.

If the decision is made to see the patient physically, then the patient as well as all members of the rheumatology team should do everything necessary to prevent SARS-CoV-2 infection during the visit. Since local guidance may differ, and supplies may be a limiting factor, a generic advice is given here. Personal protection equipment refers to masks, gloves, eye protection, safety footwear, gowns and hairnets, among others.

Level of agreement: 9.9±0.2; 94% scored 8/10 or higher.

Management of the RMD when local measures of social distancing are in effect

Recommendations 4–6 advise patients with RMD how to act during or in the aftermath of the SARS-CoV-2 epidemic, when official restrictions in the freedom of movement apply. They refer to all potential levels of existing social distancing, varying from, for example, keeping 1–1.5 m or 2 m distance for subpopulations to a complete country lockdown.

RC 4. If the RMD and its drug treatment are stable, and signs or symptoms of drug toxicity are absent, regular blood monitoring and face-to-face rheumatology consultations can be postponed temporarily. If necessary, consultation can take place remotely.

This recommendation tells patients with RMD and their caregivers that usual regular monitoring visits can safely be postponed once or twice (up to 6 months maximum) in patients with stable disease. Instead, patients may communicate with their rheumatologists and HPR via telephone or videoconference. Email communication is generally discouraged, because of issues with privacy protection, unless approved secure email transfer systems are used.

Level of agreement: 9.6±0.9; 94% scored 8/10 or higher.

RC 5. If the RMD is active, if drug therapy has recently been started or needs adjustment, or if signs or symptoms of drug toxicity emerge, patient and rheumatologist should liaise, weigh the risks of a visit to the clinic against the limitations of remote advice, and decide together.

This recommendation clarifies that a visit to a clinic or hospital implies a judgmental trade-off between the risk of advising the patient only remotely and the patient’s and rheumatologist/HPR’s risk of contracting SARS-CoV-2 in the hospital or care facility. A generic recommendation (dos and don’ts) cannot be formulated, since the outcome of this decision is situational and dependent on the needs of the patient and the appraisal of the physician/HPR. This may particularly be the case as COVID-safe areas of clinics and hospitals are increasingly created.

Level of agreement: 9.7±1.0; 89% scored 8/10 or higher.

RC 6. If a patient with RMD is offered an outpatient, day care or other type of hospital appointment, patients and members of the rheumatology team should follow local guidance for infection prevention and control, including the use of personal protection equipment if indicated.

If the decision is made to see the patient physically, then the patient as well as all members of the rheumatology team should do everything necessary to prevent SARS-CoV-2 infection during the visit. Since local guidance may differ, and supplies may be a limiting factor, a generic advice is given here. Personal protection equipment refers to masks, gloves, eye protection, safety footwear, gowns and hairnets, among others.

Level of agreement: 9.9±0.2; 94% scored 8/10 or higher.
Recommendation

Members argued whether or not a ‘lowest possible dose’ should be recommended specifically, but agreed that the principle of ‘lowest possible dose’ as per existing EULAR recommendations for the management of GCs\(^1\) is part of good clinical practice and valid under all circumstances.

Level of agreement: 8.8±1.6; 79% scored 8/10 or higher.

RC 9. If patients with RMD experience mild* symptoms of COVID-19, potential treatment changes in DMARDs should be discussed on a case-by-case basis.

It is currently assumed that at least 80% of patients with COVID-19 will experience a relatively mild course.\(^2\) This recommendation reiterates that, currently, we have no reason to believe that patients with RMD and COVID-19 have an increased risk of a more severe disease course attributable to the use of DMARDs. The risks seem reasonably low and some DMARDs are less suspected than others. The opinions in the task force were divided on whether or not DMARDs should be paused and, if yes, which ones. Theoretically, some DMARDs may even be protective (eg, HCQ, IL-6 inhibitors, tumour necrosis factor inhibitors, JAKi), while for others (eg, methotrexate) pausing for a short period of time is futile due to their pharmacokinetic properties.

The task force finally agreed that, on balance, patient’s fears and beliefs may be decisive. They finally agreed on a recommendation for a case-by-case judgement. That means: rheumatologists should not automatically advise a patient to stop DMARDs in case of mild symptoms of COVID-19 but, if the patient feels safer by pausing a DMARD for a while, and the rheumatologist believes that there is no increased risk of RMD complications, pausing the DMARD may be a defendable decision.

NSAIDs, under suspicion for a short while,\(^3\) can as far as we know be used without additional risk and deserve no further specific mention in the recommendation. In the risk assessment process, it should be borne in mind that many of these drugs including NSAIDs and cytokine inhibitors can potentially mask certain COVID-19 symptoms such as fever. Note also that IL-6 inhibitors and JAKi decrease the acute phase response irrespective of the clinical course.

Level of agreement: 8.9±1.4; 84% scored 8/10 or higher.

RC 10. Patients with RMD and initially mild symptoms who experience worsening** of COVID-19 symptoms should immediately seek further healthcare advice of an expert in treating COVID-19, such as a pulmonologist, an internist or a specialist treating expert.

This recommendation particularly mentions pneumococci and influenza since they may create clinical confusion with COVID-19. This recommendation particularly mentions pneumococci and influenza since they may create clinical confusion with COVID-19, and the results of a very recent trial comparing low-dose and high-dose chloroquine, for instance, suggest that high-dose chloroquine, in use in many hospitals, may increase mortality rather than decrease it.\(^2\)

The reasoning can also be turned around: if the rheumatologist truly believes that a particular drug may be effective but formal proof is still lacking (a situation that may arise in view of DMARDs which are now investigated for the treatment of COVID-19), he should first try to ‘convince’ the local hospital’s protocol committee to adjust the existing local treatment protocol rather than acting on his own. Preferably, the management of patients with RMD with significant COVID-19 is a multidisciplinary matter; the consensual decision of a multidisciplinary team should be credited a higher weight than the opinion of one physician.

Level of agreement: 9.7±0.8; 89% scored 8/10 or higher.

Prevention of other infections than SARS-CoV-2

Recommendations 12 and 13 remind the rheumatologist and HPR who care for patients with RMD of other important infectious diseases to consider in these patients. There are two reasons to focus on other infectious diseases: (1) Avoiding confusion between COVID-19 and phenotypical mimics. (2) Avoiding severe morbidity due to neglected coexisting infections. While these recommendations focus on three particular pathogens (pneumococci, influenza and *Pneumocystis jirovecii*), consideration of other infectious diseases should not be limited to these entities.

RC 12. Patients with RMD without symptoms of COVID-19 should be advised to update their vaccination status in accordance with the EULAR recommendations for the vaccination of patients with RMD, with a particular focus on pneumococci and influenza.

This recommendation is a generic one aimed at optimising public health adherence. The EULAR vaccination recommendations have recently been updated using the most contemporary evidence existing for other infections than SARS-CoV-2.\(^4\) This recommendation particularly mentions pneumococcus and influenza since they may create clinical confusion with COVID-19.

Level of agreement: 9.4±1.0; 89% scored 8/10 or higher.

RC 13. In patients with RMD treated with cyclophosphamide or GCs, *Pneumocystis jiroveci pneumonia prophylaxis should be considered*. This recommendation pertains to patients with RMD with severe lupus, severe vasculitis or systemic sclerosis, among others. It reiterates a general recommendation\(^4\) and is mentioned here since pneumocystis Jiroveci pneumonia (PJP) may be clinically confused with COVID-19 pneumonia, and since PJP is an avoidable condition and it may be expected that the coexistence of PJP and COVID-19 pneumonia implies a worse prognosis.

Level of agreement: 9.3±0.9; 89% scored 8/10 or higher.

DISCUSSION

These 5 OPs and 13 recommendations form the first EULAR set of recommendations for the management of patients with COVID-19.
RMD during the COVID-19 pandemic. While they provide the best possible consensus guidance according to international experts, it is self-evident that their scientific status is meagre. The level of evidence never exceeds that of ‘expert opinion’ and the strength of recommendation is therefore axiomatically low.

The task force expects and hopes that the life span of several of these recommendations will be short, far shorter than usual, as a reflection of the accrual of solid scientific evidence that may fuel better recommendations and the advent of effective drugs for COVID-19 and its complications.

Comparing these EULAR recommendations with other recent recommendations, such as the American Society of Rheumatology (ACR) recommendations and those from Germany and the UK, reveals, as expected, high levels of similarity, which is reassuring. Issues of controversy are sparse and of relatively minor importance. Formulated in a more negative tone, one may say that professional organisations are currently ‘flying blind’, due to the novelty and the impact of the pandemic and the lack of methodologically sound evidence. Such a situation is unprecedented for all professional medical organisations including ours. Providing meaningful guidance under such circumstances asks for creative solutions that are not prescribed by standard operating procedures. Many of these outstanding questions about COVID-19 in the field of RMD should be addressed in the near future. The task force hopes that the release of these expert-opinion-based recommendations meant for patients with RMD and their caregivers in ‘COVID-time’ will be a stimulus to initiate and conduct this research.

**Author affiliations**

1 Amsterdam Rheumatology Center, AMC, Amsterdam, The Netherlands

2 Rheumatology, Zuyderland MC, Heerlen, The Netherlands

3 Centre for Rheumatology & Department of Neurumuscular Diseases, University College London, London, UK

4 Rheumatology, Leiden University Medical Center, Leiden, The Netherlands

5 Rheumatology, UMCGrechter, Utrecht, The Netherlands

6 Rheumatology and Clinical Immunology, Charité University Hospital, Berlin, Germany

7 Department of Rheumatology, Instituto de Salud Musculoesquelética, Madrid, Spain

8 Immunorheumatology, CHU Lapeyronie, Montpellier, France

9 Department of infectious diseases, Universita degli Studi di Milano, Milano, Italy

10 Institut Pierre Louis d’Épidémiologie et de Santé Publique, INSERM, Sorbonne Université, Paris, France

11 APHP, Rheumatology Department, Hopital Universitaire Pitie Salpetriere, Paris, France

12 ScienCe Clinique e Biologiche, Università degli Studi di Torino, Torino, Italy

13 Newcastle University and Newcastle upon Tyne Hospitals NHS Foundation Trust, Institute of Cellular Medicine, Newcastle upon Tyne, UK

14 Rheumatology, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpitaux universitaires Paris-Sud – Hôpital Bicêtre, Le Kremlin Bicêtre, France

15 Université Paris-Sud, Center for Immunology of Viral Infections and Auto-immune Diseases (IMVA), Institut pour la Santé et la Recherche Médicale (INSERM) UMR 1184, Université Paris-Saclay, Le Kremlin Bicêtre, France

16 Institute of Infectious, Immunity and Inflammation, University of Glasgow, Glasgow, UK

17 Rheumatology and Clinical Immunology, Giessen University, Bad Nauheim, Germany

18 National Heart & Lung Institute, Imperial College London Faculty of Medicine, London, UK

19 Department of Rheumatology, Medical University of Vienna, Wien, Austria

20 Section for Outcomes Research, Medical University of Vienna, Vienna, Austria

21 Deutsche Rheuma-Liga, Bonn, Germany

22 Division of Rheumatology and Clinical Immunology, Department of Medicine IV, Ludwig Maximilian University of Munich, Munich, Germany

**Twitter** Pedro M Machado @pedrommcmachado and John D Isaacs @ProfJohnIsaacs

**Contributors** All authors are members of EULAR’s task force for the development of recommendations for patients with RMD in the context of SARS-CoV-2 and COVID-19. They all have contributed to the work and read and finally approved the manuscript for submission.

**Funding** The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

**Competing interests** RBML received honoraria for lecturing and consultation from AbbVie, Amgen, BMS, Cellgene, Galapagos, Gilead, Janssen, Eli Lilly, Novartis, Pfizer, UCB and is owner and director of Rheumatology Consultancy BV. PMM received consulting/speaker’s fees from Abbvie, BMS, Cellgene, Eli Lilly, Janssen, MSD, Novartis, Pfizer, Roche and UCB and is supported by the National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research Centre (BRC). The views expressed are those of the authors and not necessarily those of the (UK) National Health Service (NHS), the NIHR, or the (UK) Department of Health. LG received research grants from Lilly, Pfizer, Sandoz; and consulting fees from AbbVie, Amgen, BMS, Biogen, Cellgene, Janssen, Lilly, Novartis, Pfizer, Sanofi-Aventis and UCB. GRB received honoraria for lectures and consulting from AbbVie, Amgen, BMS, Gilead, Janssen, Lilly, Novartis, Pfizer, Sanofi-Aventis, Roche, UCB and consulting fees from AbbVie, BMS, Gilead, Janssen, Lilly, Merck, Novartis, Pfizer, Roche-Chugai, Sanofi and UCB; and research grants from Novartis and Pfizer and Roche. JSS received grants to his institution from Abbvie, AstraZeneca, Astra, Bristol-Myers Squibb, Cellgene, Celltrion, Chugai, Gilead, IUTO Pharma, Janssen, Lilly, MSD, Novartis/Sandoz, Pfizer, Roche, Samsung, Sanoﬁ and UCB. JDI received research grants from Pfizer and honoraria for lectures and/or consulting from AbbVie, Amgen, Eli Lilly, Gilead, Merck & Co, Roche and UCB. MG received honoraria for lectures and consulting and grants to his institution: AbbVie, BMS, Gilead, Janssen, Novartis, MSD, AstraZeneca, Vifor; HS-K received honoraria for lectures and consulting from AbbVie, Amgen, BMS, Gilead, Janssen, Lilly, Novartis, Pfizer, Sanofi-Aventis, Roche and UCB. IM received research grants from Lilly, Pfizer, BMS, Cellgene, Janssen, and consulting fees from AbbVie, BMS, Cellgene, Gilead, Janssen, Lilly, Novartis, Pfizer, Sanofi-Aventis and UCB.

**Patient and public involvement** Patients and/or the public were not involved in the design, conduct, or reporting, or dissemination plans of this research.

**Patient consent for publication** Not required.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data availability statement** All data relevant to the study are included in the article.

This article is made freely available for use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.

**ORCID iDs**

Robert BM Landewé http://orcid.org/0000-0002-0577-6620

Pedro M Machado http://orcid.org/0000-0002-8411-7972

Feline Kroon http://orcid.org/0000-0002-8940-0582

Laure Gossec http://orcid.org/0000-0002-4528-310X

John D Isaacs http://orcid.org/0000-0002-6130-7056

Tanja A Stamm http://orcid.org/0000-0003-3073-7284

Hendrik Schulze-Koops http://orcid.org/0000-0002-1681-491X

**REFERENCES**


857
Recommendation


